Dachaigh › Gnìomhan › Regulatory Affairs Managers › Cambridge, MA
Regulatory Affairs Managers ann an Cambridge, MA: Tuarastalan H-1B
99 iarrtasan cumhaichean-obrach airson an dreuchd seo le làrach-obrach ann an Cambridge, MA. Tuarastal bunasach meadhanach $169,288; leth meadhanach $146,928–$196,379.
A rèir ìre tuarastail
| Ìre tuarastail | Tuarastal meadhanach |
|---|---|
| Ìre I (innte) | $130,000 |
| Ìre II (càileachail) | $155,000 |
| Ìre III (eòlach) | $183,950 |
| Ìre IV (gu lèir comasach) | $213,000 |
Suidhichidh Roinn an Obrach ceithir ìrean tuarastail làithreach airson gach dreuchd agus sgìre, bho Ìre I (inntrigeadh) gu Ìre IV (gu tur comasach). Taghaidh an neach-fastaidh an ìre a fhreagras ri riatanasan na h-obrach.
Luchd-fastaidh
| Neach-obrach | LCAs | Tuarastal meadhanach |
|---|---|---|
| Takeda Development Center Americas, Inc. | 32 | $185,065 |
| Sanofi US Services Inc. | 13 | $133,026 |
| Blueprint Medicines Corporation | 6 | $152,286 |
| Beam Therapeutics, Inc. | 5 | $200,000 |
| Intellia Therapeutics | 4 | $176,450 |
| Sage Therapeutics, Inc. | 4 | $160,416 |
| Genzyme Corporation | 4 | $132,782 |
| BioNTech US Inc. | 3 | $188,000 |
| Sarepta Therapeutics, Inc. | 3 | $190,000 |
| Alnylam US, Inc. | 3 | $140,000 |
| Syros Pharmaceuticals, Inc. | 3 | $316,323 |
| UKA North America LLC | 2 | $155,000 |
| ModernaTX, Inc. | 2 | $216,100 |
| Biogen Inc. | 1 | $120,078 |
| nference, inc. | 1 | $160,000 |
| Evelo Biosciences, Inc. | 1 | $209,000 |
| Omega Therapeutics, Inc. | 1 | $215,000 |
| Moderna Services, Inc. | 1 | $180,294 |
| Boston Pharmaceuticals | 1 | $188,780 |
| Novartis Pharmaceuticals Corporation | 1 | $150,176 |
| BlueRock Therapeutics LP | 1 | $145,000 |
| InterSystems Corporation | 1 | $157,247 |
| BeiGene USA, Inc. | 1 | $175,000 |
| Concert HealthAI ManagementCo, LLC | 1 | $195,458 |
| Kadmon Corporation, LLC | 1 | $120,000 |
| Ipsen Biopharmaceuticals, Inc. | 1 | $210,891 |
| Regeneron Pharmaceuticals, Inc. | 1 | $220,000 |
| QuantCo, Inc. | 1 | $135,000 |
Tiotalan dreuchd
- Director, Global Regulatory Affairs4
- Senior Manager, Pharmacovigilance Operations3
- Senior Manager, Regulatory Affairs3
- Regulatory Strategist3
- Senior Manager, Global Regulatory Affairs, Marketed Products3
- GRA Device Lead Specialty Care Device & Combination Products3
- Associate Director2
- Associate Director, Regulatory Affairs2
- Associate Director, Regulatory Strategy2
- Manager, PV Validation2
- Director, Regulatory Affairs2
- Associate Director, CMC Program Lead, Cell Therapies2
- Project Developer2
- Safety Governance Expert2
- SVP Global Regulatory Affairs & Quality & Op Excellence2
Luchd-taic H-1B ann an Cambridge, MA →
Is e na tuarastalan an ìre as ìsle den tuarastal a chaidh a thabhann air gach iarrtas, air an tionndadh gu suim bhliadhnail; cleachdaidh na staitistigean iarrtasan làn-aimsire le teisteanas a-mhàin. Chan eil LCA na aontachadh bhìosa agus faodaidh aon LCA còmhdach a dhèanamh air iomadh dreuchd. Stòr: Roinn an Obrach na SA, Dàta Foillseachaidh OFLC LCA, bliadhnaichean ionmhais 2023–2026 (co-dhùnadh as ùire 30 Ògmh 2026).